

## MINI-REVIEW

# Ketogenic diet: a therapeutic alternative in pediatric refractory epilepsies

Amina Chentouf \* 

Faculty of Medicine, Department of Neurology- Oran University-Hospital. Pediatric Accidentology Research Laboratory ACCIPED, Oran1 Ahmed BENBELLA University, 31000 Oran, Algeria

## Abstract

Several studies have demonstrated the effectiveness of ketogenic diet (KD) on refractory epilepsies, especially in children. In this category of patients, a strong collaboration between the healthcare providers and the full engagement of parents is required. The regimen is significantly effective for different types of epilepsy that are resistant to medical treatment. It can also be used as a first-line treatment, given its well tolerance. Treatment has been rolled out for children but research into its use in adults is promising. There is no international or national protocol, the implementation of this diet follows a rigor being specific to every ketogenic center. The understanding of the underlying mechanisms is not well elucidated, it would make it possible to optimize the clinical use of the ketogenic diet, but also to develop novel antiepileptic treatments. This article aims to review the different variants of KD and their prescription terms in children with intractable epilepsy.

**Keywords:** drug-resistant epilepsy, ketogenic diet, children, Modified Atkins Diet.

Received: December 04, 2021 / Accepted: February 13, 2022 / Published: February 27, 2022

## 1 Introduction

Epilepsy constitutes a brain disorder characterized by a lasting predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological and social consequences of this condition <sup>1</sup>. Epilepsy is a common pathology affecting 65 to 70 million people worldwide <sup>2</sup>. The management of this chronic disease aims to control seizures while preserving the patient's quality of life (QOL) <sup>3</sup>. Treatment is based on anti-epileptic drugs, which help control seizures in more than two-thirds of cases. Nevertheless, nearly one third of patients will continue to have seizures despite a well-conducted treatment, thus justifying the use of further therapies such as ketogenic diet (KD) or surgery <sup>4</sup>.

KD is a high-fat (providing a range of 55 to 90% calories as fat), adequate protein (accounts for 30-35% of the daily caloric requirement supplied; minimum of 1 g/kg of protein), low-carbohydrate diet (only 5-10% of total calorie intakes are provided by carbohydrates, less than 50 g/day) <sup>5</sup>. The term KD currently refers to any dietary therapy which results in a metabolic ketogenic state. Ketones can result from the breakdown of fat; it is then an oxidation of fatty acids, secondary to a restriction in carbohydrates. Several studies have demonstrated the effectiveness of KD on refractory epilepsies especially in children <sup>6</sup>. Although KD is not a substitute for pharmacological treatments, it often reduces the number of antiepileptic drugs taken as combination therapy as well as their dosages <sup>7</sup>. This article reviews the different variants of KD and their prescription terms in children with intractable epilepsy.


## 2 Mechanism of action

Despite the use of KD for a hundred years, its antiepileptic mechanisms are not yet fully elucidated. The anticonvulsant effects of the KD have been studied primarily in rodent models exposed to electrical stimuli (e.g., pentylenetetrazol, maximal electroshock) <sup>8</sup> resulting in several hypotheses:

- The first mechanism proposed was the direct action of the ketone bodies, namely acetone, acetoacetate and  $\beta$ -hydroxybutyrate (BHB). Although many studies have attempted to establish a causal link between the blood level of BHB and the anticonvulsant effect of KD, no significant association has been demonstrated <sup>9</sup>. However, it is known that ketone bodies cause an overproduction of energy by the mitochondria. In addition, the ketogenic diet causes an increase in the number of mitochondria in the brain. This increase in energy capacity would stabilize synaptic transmission and raise the epileptogenic threshold <sup>10</sup>. Moreover, BHB appears to exert both epigenetic (inhibition of histone deacetylases) and anti-inflammatory activity. While these two effects of BHB have yet to be directly linked to epileptogenesis, parallel lines of evidence indicate that histone deacetylases inhibition and a reduction in neuroinflammation can block seizure activity <sup>11</sup>;
- Another mechanism considered in relationship with the reduction in the use of glucose in the brain, which can lead to the activation of ATP-dependent potassium channels (Figure 1). The opening of these widely distributed channels in the central nervous system leads to neural membrane hyperpolarization, thereby reducing electrical excitability in the brain and raising seizure threshold <sup>9</sup>;

- The modulation of different neurotransmission systems is also suspected to be part of the mechanism of action of the KD, including those of monoamines, glutamate and  $\gamma$ -aminobutyric acid (GABA). Indeed, it has been observed that dopamine and serotonin concentrations are lowered in the cerebrospinal fluid of children with epilepsy treated with KD <sup>12</sup>. As for glutamate, which is the main excitatory neurotransmitter involved in the state of hyperexcitability encountered in epilepsy, its release by neurons would be reduced by acetoacetate which would have an inhibitory effect on the vesicular transporter VGLUT2 <sup>13</sup>. Conversely, the extracellular concentration of GABA, which is the main inhibitory neurotransmitter of the nervous system, could be increased by the KD through an alteration in the activity of enzymes for the synthesis and degradation of GABA <sup>10</sup>.

A neuroprotective action of the KD is also being investigated. However, since diet-based therapy is likely to cause a wide range of biochemical, molecular, and cellular changes, it is highly probable that the systemic effects resulting from KD are not due to a single mechanism <sup>7</sup>.



**Figure 1:** Multiple proposed anti-epileptogenic effects of the ketogenic diet involve the metabolism of ketone bodies in the mitochondria. A. products of mitochondrial metabolism of ketone bodies in neurons that are proposed to confer anti-epileptic effects. B. The effects of certain products from A on ion transfer at the synapse. A<sub>1</sub>R, adenosine A 1 receptor; ACA, acetoacetate; b-HB, beta hydroxybutyrate; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species <sup>13</sup>.

### 3 Ketogenic diet and its variants

#### 3.1 Classic ketogenic diet

Ketogenic diet is based on a particular weight proportionality between fat and the "non-fat" (carbohydrates and proteins) of the diet. Thus, if the diet provides four servings of fat for one serving of "non-fat", then the ratio is said to be "4: 1" <sup>14</sup>.

There are other possible ratios: "1: 1", "2: 1", "3: 1" or "5: 1". The more ketogenic the calorie ratio, the more effective the diet, but tolerance is poor.

A study has shown that the "4: 1" ratio is more effective in reducing seizures than the "3: 1" ratio but tolerance is better for the "3: 1" ratio <sup>15</sup>.

The rate of carbohydrate decreases depending on the type of diet selected. As the rate of protein is fixed for growth, the rate of vegetables and fruit is increasingly reduced <sup>16</sup>. However, particular diet should be adjusted to particular clinical situation.

The intensity of the diet depends on the age of the child:

- For children under 3 years old, a "3: 1" diet is preferred;
- For children over 3 years and adults, a "4: 1" diet is recommended provided that the protein intake allows an acceptable level of carbohydrate (more than 15 g per day) <sup>17</sup>.

#### 3.2 Modified Atkins Diet

This diet consists of a supply of fats and proteins without caloric restriction while the daily amount of glucose is limited. In addition, the proportion of fat and protein provided is less strict than in the classic ketogenic diet. It is recommended to start the diet with a daily carbohydrate intake of 10 g / day for the first three months. It is then feasible to increase depending on the clinical course to 20 g / day if the restriction is poorly tolerated <sup>18</sup>. This diet induces ketosis within four days without prior fasting <sup>19</sup> and has the advantage of being more permissive than the classic diet, thus improving compliance.

#### 3.3 Diet with a low glycemic index

Food with a low glycemic index are food that are responsible for low changes in blood sugar and insulin levels. They are mainly represented by meats, certain vegetables and cereals <sup>20</sup>. The effectiveness of this diet in the treatment of epilepsy in both adults and children has been demonstrated by two studies <sup>20,21</sup>.

### 4 Indications

Ketogenic diet is an integral part of the therapeutic arsenal for refractory epilepsies which account for 20 to 30% of all epilepsies. It has been shown to be effective in a number of syndromes <sup>22</sup> such as West's syndrome (or infantile spasms) <sup>23</sup>, myoclonic astatic epilepsy <sup>24</sup>, Dravet syndrome <sup>25</sup> or even Lennox-Gastaut syndrome <sup>26</sup> and tuberous sclerosis of Bourneville <sup>27</sup>.

Ketogenic diet is also a treatment for metabolic diseases such as glucose transporter deficiency (Glut-1 deficiency) or pyruvate dehydrogenase deficiency. In these two diseases, it is the unique treatment to have shown efficacy in providing the brain with an alternative energy source than glucose <sup>28,29</sup>.

### 5 Contraindications

The presence of any of the following issues precludes the establishment of KD: <sup>30</sup>

- Abnormalities in the oxidation of fatty acids;
- Deficiency of gluconeogenesis, ketogenesis;

- Pyruvate-carboxylase deficiency;
- Liver failure;
- Kidney disease;
- Diabetes mellitus Type 1;
- Pregnancy;
- Cardiac arrhythmias;
- Recent stroke or myocardial infarction;
- Heart failure;
- Respiratory failure;
- Malignancy;
- Non adherence to the diet.

A preliminary assessment is necessary to determine whether the initiation of KD is possible <sup>31</sup>.

## 6 Drugs interactions

The combination of KD with certain antiepileptic drugs should be carefully monitored.

Patients on carbonic anhydrase inhibitors such as Topiramate or Zonisamide require careful monitoring because of the risk of kidney stones <sup>32</sup>.

There are no formal contraindications with performing general anesthesia in patients on a ketogenic diet. However, there is a precaution for use with respect to a particular anesthetic, propofol, with which a case of death has been observed <sup>33,34</sup>.

There is no benefit in modifying the dosage of antiepileptics because KD has been shown not to modify their plasma levels <sup>35</sup>. On the other hand, the effectiveness of KD can allow a reduction in the dosage of antiepileptics or even a discontinuation.

## 7 Implementation of ketogenic diet

The implementation of KD in children must be initiated in a hospital environment under the close supervision of a well-trained team in order to ensure optimal education of the family <sup>36</sup>. The child's eating habits are evaluated by the dietitian who will judge the feasibility of the diet and who will instruct the parents on the importance of good compliance with the diet and intolerance signs. These signs are mainly observed in infants and are mainly represented by hypoglycemia and hyperketosis <sup>36</sup>.

Hypoglycemia is manifested by restlessness, hypotonia, lethargy, skin pallor, and even hypothermia with cyanosis. Hyperketosis clinically manifests as polypnea, tachycardia, skin flushing, irritability, vomiting with the odor of acetone.

Some teams initiate the diet with an initial fasting period of 24 to 48 hours to achieve faster seizure control, particularly in pediatric intensive care in the context of status epilepticus <sup>37</sup>.

The international Ketogenic Diet study group recommends laboratory tests before starting the diet <sup>38</sup> (Table 1). During the first days of the diet, monitoring of capillary glycemia and the presence of urinary ketone bodies is required several times a day <sup>39</sup>.

**Table 1:** Laboratory examinations before ketogenic diet initiation <sup>38</sup>

<b>Required exams</b>	Glycemia and vitamin D Blood count and platelets Blood serum ionogram Bicarbonates Plasma proteins Calcium, Magnesium, Phosphate Hepatic tests (albumin, ASAT, ALT) Kidney function (urea, creatinine) Lipid profile Plasma acylcarnitine profiles Calciuria and creatininuria, Chromatography of urinary organic acids
<b>Recommended exams</b>	Vitamins A, E, B12, Zinc
<b>Optional exams</b>	Renal ultrasound if family history of renal lithiasis Electroencephalogram Magnetic resonance imaging Cerebrospinal fluid analysis Electrocardiogram

## 8 Efficacy

The diet's effectiveness has been demonstrated by two randomized trials: one for the classic ketogenic diet and one for the modified Atkins diet <sup>37,40</sup>.

The effectiveness of KD is assessed by the reduction in the frequency of seizures, which is a priori not correlated with ketonuria or ketonemia <sup>41</sup>. The antiepileptic effect of the modified Atkins-type or low glycemic index ketogenic diet appears to be comparable to that of the "4: 1" ketogenic diet <sup>42</sup>.

It is possible that other positive effects of diet exist, particularly on behavior and cognition. It has been suggested that in addition to its effect on seizure frequency, the ketogenic diet may also improve attention and cognitive functions <sup>43</sup>.

After the introduction of the ketogenic diet, 75% of children are responders at 14 days and 90% at 23 days. In the long term, 75% of children have a reduction of more than 50% of seizures and 48% see their frequency of seizures decrease by more than 90% at 3 months <sup>44</sup>.

## 9 Duration of the ketogenic diet

It is recommended to maintain the ketogenic diet for at least 3 months before judging its effectiveness. When it is effective, it is followed up for 2 years with the possibility of gradually increasing the proportion of carbohydrates <sup>39</sup>.

The diet is stopped approximately after two years in children whose number of seizures has decreased by more than 50% and can be continued until 6 to 12 years for responders over 90%, in the absence of adverse effects <sup>45</sup>.

## 10 Follow up

Children on a ketogenic diet should be monitored regularly, both by the dietitian and by the neurologist. Initially, the children are seen every 2-3 months and then after one year of diet the monitoring is spaced every six months.

At each visit, body weight, height, and head circumference should be measured to track growth. The treatment should be reassessed as well as compliance with the regimen, its effectiveness (seizure schedule, behavior), its tolerance and any adverse effects <sup>46</sup>.

## 11 Side effects

The most encountered side effects are gastrointestinal disorders (12–50%) such as constipation, diarrhea, vomiting and abdominal pain <sup>47</sup>. Constipation can be treated with a higher fiber diet and laxative treatments. Vomiting may be due to gastroesophageal reflux or hyperketosis. This may require the setting up of a rehydration. A few cases of pancreatitis and hepatitis have also been reported <sup>48</sup>.

In case of abdominal pain, beware of the risk of renal lithiasis which may be increased by taking certain antiepileptics such as Topiramate or Zonisamide. This risk is 2-6% and can be as high as 25% for a KD of six years or more <sup>49</sup>. Some teams supplement with potassium citrate, which would reduce the risk of kidney stones by 9% <sup>50</sup>.

At the metabolic level, the main side effects are hypoglycemia, metabolic acidosis (2-5%), hyperuricemia (2-26%), hypocalcemia (2%), hypomagnesemia (5%) and hyperketosis. In case of symptomatic hypoglycemia, the child should be given sugar <sup>39</sup>. Vitamin deficiencies are also described, which therefore require supplementation with calcium and vitamin D in order to limit the risk of osteoporosis and delayed weight <sup>39</sup>.

At the cardiovascular level, KD can also lead to hypercholesterolemia <sup>51</sup>, hyper-triglyceridemia and elevated apolipoprotein B <sup>6</sup>. Isolated cases of cardiomyopathy or ECG-corrected QT interval prolongation have been reported <sup>6</sup>.

KD is also associated to higher incidence of renal calculi which can be prevented by prescribing 2 mmol potassium citrate/kg/day for the duration of treatment <sup>52</sup>.

Long-term complications are mainly represented by bone fractures and height stagnation. It is therefore recommended to perform a regular bone densitometry <sup>6</sup>.

## 12 Conclusions

Ketogenic diet and its variants are safe and effective among children with drug resistant epilepsy. This latter completely escapes the conventional therapies available today and its management is very complex. Ketogenic diet thus constitutes an interesting alternative in the face of ineffective drug combination therapy. The ketogenic diet is a therapeutic option in the treatment of drug-resistant epilepsies and certain epileptic syndromes in children. It constitutes also the first-line treatment

of certain metabolic diseases such as glucose transporter deficiency of the GLUT1 type or pyruvate dehydrogenase deficiency. There are different types of ketogenic diets including the modified Atkins diet which seems less restrictive than the classic ketogenic diet. It is essential to know the absolute and relative contraindications of the diet and its complications in order to prevent them.

Given the beneficial clinical outcomes regarding efficacy and safety, KD should be considered as a treatment option for children with refractory epilepsy who are not eligible for epilepsy surgery.

---

**Acknowledgment:** Not applicable

**Author Contribution:** A.A is the only author of this paper

**Funding:** This research did not receive any external funding.

**Conflicts of Interest:** The author declares no conflicts of interest.

---

## References

- [1] Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E., Engel, J., Jr, Forsgren, L., French, J. A., Glynn, M., Hesdorffer, D. C., Lee, B. I., Mathern, G. W., Moshé, S. L., Perucca, E., Scheffer, I. E., Tomson, T., Watanabe, M., & Wiebe, S. (2014). ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*, *55*(4), 475–482. <https://doi.org/10.1111/epi.12550>
- [2] Singh, A., & Trevick, S. (2016). The Epidemiology of Global Epilepsy. *Neurologic Clinics*, *34*(4), 837–847. <https://doi.org/10.1016/j.ncl.2016.06.015>
- [3] Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013). New avenues for anti-epileptic drug discovery and development. *Nature reviews. Drug Discovery*, *12*(10), 757–776. <https://doi.org/10.1038/nrd4126>
- [4] Kwan, P., Arzimanoglou, A., Berg, A. T., Brodie, M. J., Allen Hauser, W., Mathern, G., Moshé, S. L., Perucca, E., Wiebe, S., & French, J. (2010). Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*, *51*(6), 1069–1077. <https://doi.org/10.1111/j.1528-1167.2009.02397.x>
- [5] Di Raimondo, D., Buscemi, S., Musiari, G., Rizzo, G., Pirera, E., Corleo, D., Pinto, A., & Tuttolomondo, A. (2021). Ketogenic Diet, Physical Activity, and Hypertension-A Narrative Review. *Nutrients*, *13*(8), 2567. <https://doi.org/10.3390/nu13082567>
- [6] Sourbron, J., Klinkenberg, S., Van Kuijk, S. M., Lagae, L., Lambrechts, D., Braakman, H. M., & Majoie, M. (2020). Ketogenic diet for the treatment of pediatric epilepsy: Review and meta-analysis. *Child's Nervous System*, *36*(6), 1099–1109. <https://doi.org/10.1007/s00381-020-04578-7>
- [7] Simeone, T. A., Simeone, K. A., Stafstrom, C. E., & Rho, J. M. (2018). Do ketone bodies mediate the anti-seizure effects

- of the ketogenic diet? *Neuropharmacology*, *133*, 233–241. <https://doi.org/10.1016/j.neuropharm.2018.01.011>
- [8] Appleton, D. B., & DeVivo, D. C. (1974). An animal model for the ketogenic diet. *Epilepsia*, *15*(2), 211–227. <https://doi.org/10.1111/j.1528-1157.1974.tb04943.x>
- [9] Bough, K. J., & Rho, J. M. (2007). Anticonvulsant mechanisms of the ketogenic diet. *Epilepsia*, *48*(1), 43–58. <https://doi.org/10.1111/j.1528-1167.2007.00915.x>
- [10] Barzegar, M., Afghan, M., Tarmahi, V., Behtari, M., Rahimi Khamaneh, S., & Raiesi, S. (2021). Ketogenic diet: overview, types, and possible anti-seizure mechanisms. *Nutritional Neuroscience*, *24*(4), 307–316. <https://doi.org/10.1080/1028415X.2019.1627769>
- [11] Simeone, T. A., Simeone, K. A., & Rho, J. M. (2017). Ketone Bodies as Anti-Seizure Agents. *Neurochemical Research*, *42*(7), 2011–2018. <https://doi.org/10.1007/s11064-017-2253-5>
- [12] Lutas, A., & Yellen, G. (2013). The ketogenic diet: metabolic influences on brain excitability and epilepsy. *Trends in Neurosciences*, *36*(1), 32–40. <https://doi.org/10.1016/j.tins.2012.11.005>
- [13] Youngson, N. A., Morris, M. J., & Ballard, J. (2017). The mechanisms mediating the antiepileptic effects of the ketogenic diet, and potential opportunities for improvement with metabolism-altering drugs. *Seizure*, *52*, 15–19. <https://doi.org/10.1016/j.seizure.2017.09.005>
- [14] Martin, K., Jackson, C. F., Levy, R. G., & Cooper, P. N. (2016). Ketogenic diet and other dietary treatments for epilepsy. The Cochrane database of systematic reviews, 2, CD001903. <https://doi.org/10.1002/14651858.CD001903.pub3>
- [15] Falsaperla, R., D'Angelo, G., Praticò, A. D., Mauceri, L., Barbagallo, M., Pavone, P., Catanzaro, S., Gitto, E., Corsello, G., & Ruggieri, M. (2020). Ketogenic diet for infants with epilepsy: A literature review. *Epilepsy & Behavior*, *112*, 107361. <https://doi.org/10.1016/j.yebeh.2020.107361>
- [16] Cai, Q., Zhou, Z., Luo, R., Gan, J., Li, S., Mu, D., & Wan, C. (2017). Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: A systematic review of published prospective studies. *World Journal of Pediatrics*, *13*(6), 528–536. <https://doi.org/10.1007/s12519-017-0053-2>
- [17] Karimzadeh, P., Sedighi, M., Beheshti, M., Azargashb, E., Ghofrani, M., & Abdollahe-Gorgi, F. (2014). Low Glycemic Index Treatment in pediatric refractory epilepsy: the first Middle East report. *Seizure*, *23*(7), 570–572. <https://doi.org/10.1016/j.seizure.2014.03.012>
- [18] Kossoff, E. H., Turner, Z., Bluml, R. M., Pyzik, P. L., & Vining, E. P. (2007). A randomized, crossover comparison of daily carbohydrate limits using the modified Atkins diet. *Epilepsy & Behavior*, *10*(3), 432–436. <https://doi.org/10.1016/j.yebeh.2007.01.012>
- [19] Kang, H. C., Lee, H. S., You, S. J., Kang, d., Ko, T. S., & Kim, H. D. (2007). Use of a modified Atkins diet in intractable childhood epilepsy. *Epilepsia*, *48*(1), 182–186. <https://doi.org/10.1111/j.1528-1167.2006.00910.x>
- [20] Pfeifer, H. H., & Thiele, E. A. (2005). Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy. *Neurology*, *65*(11), 1810–1812. <https://doi.org/10.1212/01.wnl.0000187071.24292.9e>
- [21] Muzykewicz, D. A., Lyczkowski, D. A., Memon, N., Conant, K. D., Pfeifer, H. H., & Thiele, E. A. (2009). Efficacy, safety, and tolerability of the low glycemic index treatment in pediatric epilepsy. *Epilepsia*, *50*(5), 1118–1126. <https://doi.org/10.1111/j.1528-1167.2008.01959.x>
- [22] Nangia, S., Caraballo, R. H., Kang, H. C., Nordli, D. R., & Scheffer, I. E. (2012). Is the ketogenic diet effective in specific epilepsy syndromes?. *Epilepsy Research*, *100*(3), 252–257. <https://doi.org/10.1016/j.eplepsyres.2012.01.015>
- [23] Hong, A. M., Turner, Z., Hamdy, R. F., & Kossoff, E. H. (2010). Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. *Epilepsia*, *51*(8), 1403–1407. <https://doi.org/10.1111/j.1528-1167.2010.02586.x>
- [24] Wiemer-Kruel, A., Haberlandt, E., Hartmann, H., Wohlrab, G., & Bast, T. (2017). Modified Atkins diet is an effective treatment for children with Doose syndrome. *Epilepsia*, *58*(4), 657–662. <https://doi.org/10.1111/epi.13701>
- [25] Nabbout, R., Copioli, C., Chipaux, M., Chemaly, N., Desguerre, I., Dulac, O., & Chiron, C. (2011). Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. *Epilepsia*, *52*(7), e54–e57. <https://doi.org/10.1111/j.1528-1167.2011.03107.x>
- [26] Sharma, S., & Tripathi, M. (2013). Ketogenic diet in epileptic encephalopathies. *Epilepsy Research and Treatment*, *2013*, 652052. <https://doi.org/10.1155/2013/652052>
- [27] Coppola, G., Klepper, J., Ammendola, E., Fiorillo, M., Corte, R. D., Capano, G., & Pascotto, A. (2006). The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. *European Journal of Paediatric Neurology*, *10*(3), 148–151. <https://doi.org/10.1016/j.ejpn.2006.03.001>
- [28] Scholl-Bürgi, S., Höller, A., Pichler, K., Michel, M., Haberlandt, E., & Karall, D. (2015). Ketogenic diets in patients with inherited metabolic disorders. *Journal of Inherited Metabolic Disease*, *38*(4), 765–773. <https://doi.org/10.1007/s10545-015-9872-2>
- [29] Veggiotti, P., Teutonico, F., Alfei, E., Nardocci, N., Zorzi, G., Tagliabue, A., De Giorgis, V., & Balottin, U. (2010). Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. *Brain & Development*, *32*(5), 404–408. <https://doi.org/10.1016/j.braindev.2009.04.013>



- [30] Kossoff, E. H., & Dorward, J. L. (2008). The modified Atkins diet. *Epilepsia*, *49*, 37-41. <https://doi.org/10.1111/j.1528-1167.2008.01831.x>
- [31] Van der Louw, E., Van den Hurk, D., Neal, E., Leiendecker, B., Fitzsimmon, G., Dority, L., Thompson, L., Marchió, M., Dudzińska, M., Dressler, A., Klepper, J., Auvin, S., & Cross, J. H. (2016). Ketogenic diet guidelines for infants with refractory epilepsy. *European Journal of Paediatric Neurology*, *20*(6), 798-809. <https://doi.org/10.1016/j.ejpn.2016.07.009>
- [32] Sampath, A., Kossoff, E. H., Furth, S. L., Pyzik, P. L., & Vining, E. P. (2007). Kidney stones and the ketogenic diet: risk factors and prevention. *Journal of Child Neurology*, *22*(4), 375-378. <https://doi.org/10.1177/0883073807301926>
- [33] Watanabe, M., Tuccinardi, D., Ernesti, I., Basciani, S., Mariani, S., Genco, A., Manfrini, S., Lubrano, C., & Gnassi, L. (2020). Scientific evidence underlying contraindications to the ketogenic diet: An update. *Obesity Reviews*, *21*(10). <https://doi.org/10.1111/obr.13053>
- [34] McArtney, R., Bailey, A., & Champion, H. (2016). What is a ketogenic diet and how does it affect the use of medicines? *Archives of Disease in Childhood - Education & Practice Edition*, *102*(4), 194-199. <https://doi.org/10.1136/archdischild-2014-307000>
- [35] Coppola, G., Verrotti, A., D'Aniello, A., Arcieri, S., Operto, F. F., Della Corte, R., Ammendola, E., & Pascotto, A. (2010). Valproic acid and phenobarbital blood levels during the first month of treatment with the ketogenic diet. *Acta Neurologica Scandinavica*, *122*(4), 303-307. <https://doi.org/10.1111/j.1600-0404.2010.01359.x>
- [36] Gerdes, M., Selim, L., Girgis, M., El Ghannam, A., Abdelghaffar, H., & El-Ayadi, A. (2019). Implementation of ketogenic diet in children with drug-resistant epilepsy in a medium resources setting: Egyptian experience. *Epilepsy & Behavior Case Reports*, *11*, 35-38. <https://doi.org/10.1016/j.ebcr.2018.11.001>
- [37] Bergqvist, A. G., Schall, J. I., Gallagher, P. R., Cnaan, A., & Stallings, V. A. (2005). Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy. *Epilepsia*, *46*(11), 1810-1819. <https://doi.org/10.1111/j.1528-1167.2005.00282.x>
- [38] Kossoff, E. H., Zupec-Kania, B. A., Amark, P. E., Ballaban-Gil, K. R., Christina Bergqvist, A. G., Blackford, R., Buchhalter, J. R., Caraballo, R. H., Helen Cross, J., Dahlin, M. G., Donner, E. J., Klepper, J., Jehle, R. S., Kim, H. D., Christiana Liu, Y. M., Nation, J., Nordli, D. R., Jr, Pfeifer, H. H., Rho, J. M., Stafstrom, C. E., ... International Ketogenic Diet Study Group (2009). Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. *Epilepsia*, *50*(2), 304-317. <https://doi.org/10.1111/j.1528-1167.2008.01765.x>
- [39] Luat, A. F., Coyle, L., & Kamat, D. (2016). The ketogenic diet: A practical guide for pediatricians. *Pediatric Annals*, *45*(12). <https://doi.org/10.3928/19382359-20161109-01>
- [40] Sharma, S., Sankhyan, N., Gulati, S., & Agarwala, A. (2013). Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. *Epilepsia*, *54*(3), 481-486. <https://doi.org/10.1111/epi.12069>
- [41] Auvin, S., Porta, N., Pourrat, M., Bellavoine, V., & Vallée, L. (2010). Evolution de la prescription du regime cétogène en France chez l'enfant entre 2001 et 2008. *Revue Neurologique*, *166*(3), 314-320. <https://doi.org/10.1016/j.neurol.2009.06.006>
- [42] Kossoff, E. H., Cervenka, M. C., Henry, B. J., Haney, C. A., & Turner, Z. (2013). A decade of the modified Atkins diet (2003-2013): Results, insights, and future directions. *Epilepsy & Behavior*, *29*(3), 437-442. <https://doi.org/10.1016/j.yebeh.2013.09.032>
- [43] Jfff, D. M., Postulart, D., Lambrechts, D. A., Majoie, M. H., De Kinderen, R. J., Hendriksen, J. G., Evers, S. M., & Aldenkamp, A. P. (2016). Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: A randomized controlled trial. *Epilepsy & Behavior*, *60*, 153-157. <https://doi.org/10.1016/j.yebeh.2016.04.033>
- [44] Kossoff, E. H., Laux, L. C., Blackford, R., Morrison, P. F., Pyzik, P. L., Hamdy, R. M., Turner, Z., & Nordli, D. R., Jr (2008). When do seizures usually improve with the ketogenic diet? *Epilepsia*, *49*(2), 329-333. <https://doi.org/10.1111/j.1528-1167.2007.01417.x>
- [45] Dressler, A., & Trimmel-Schwahofer, P. (2020). The ketogenic diet for infants: How long can you go? *Epilepsy Research*, *164*, 106339. <https://doi.org/10.1016/j.eplepsyres.2020.106339>
- [46] Goswami, J. N., & Sharma, S. (2019). Current perspectives on the role of the ketogenic diet in epilepsy management. *Neuropsychiatric Disease and Treatment*, *15*, 3273-3285. <https://doi.org/10.2147/ndt.s201862>
- [47] Ułamek-Kozioł, M., Czuczwar, S. J., Januszewski, S., & Pluta, R. (2019). Ketogenic Diet and Epilepsy. *Nutrients*, *11*(10), 2510. <https://doi.org/10.3390/nu11102510>
- [48] Lin, A., Turner, Z., Doerrer, S. C., Stanfield, A., & Kossoff, E. H. (2017). Complications during ketogenic diet initiation: Prevalence, treatment, and influence on seizure outcomes. *Pediatric Neurology*, *68*, 35-39. <https://doi.org/10.1016/j.pediatrneurol.2017.01.007>
- [49] Groesbeck, D. K., Bluml, R. M., & Kossoff, E. H. (2007). Long-term use of the ketogenic diet in the treatment of epilepsy. *Developmental Medicine & Child Neurology*, *48*(12), 978-981. <https://doi.org/10.1111/j.1469-8749.2006.tb01269.x>
- [50] McNally, M. A., Pyzik, P. L., Rubenstein, J. E., Hamdy, R. F., & Kossoff, E. H. (2009). Empiric use of

- potassium citrate reduces kidney-stone incidence with the ketogenic diet. *Pediatrics*, *124*(2), e300-e304. <https://doi.org/10.1542/peds.2009-0217>
- [51] Chen, H., Chen, Y. H., Liu, L., & Wang, Y. (2019). Effects of ketogenic diet on lipid metabolism in children with intractable epilepsy. *Chinese Journal of Contemporary Pediatrics*, *21* (5), 450-453. <https://doi.org/10.7499/j.issn.1008-8830.2019.05.010>
- [52] Furth, S. L., Casey, J. C., Pyzik, P. L., Neu, A. M., Docimo, S. G., Vining, E. P., Freeman, J. M., & Fivush, B. A. (2000). Risk factors for urolithiasis in children on the ketogenic diet. *Pediatric Nephrology*, *15*(1-2), 125-128. <https://doi.org/10.1007/s004670000443>

Cite this article as: Chentouf, A. Ketogenic diet: a therapeutic alternative in pediatric refractory epilepsies. *The North African Journal of Food and Nutrition Research*, *6*(13): 39-45. <https://doi.org/10.51745/najfnr.6.13.39-45>

© 2022 The Author(s). This is an open-access article. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.